CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients.
Read SW, Lempicki RA, Di Mascio M, Srinivasula S, Burke R, Sachau W, Bosche M, Adelsberger JW, Sereti I, Davey RT Jr, Tavel JA, Huang CY, Issaq HJ, Fox SD, Lane H, Kovacs JA.
Read SW, et al. Among authors: sereti i.
J Infect Dis. 2008 Sep 15;198(6):843-50. doi: 10.1086/591250.
J Infect Dis. 2008.
PMID: 18684102
Free PMC article.